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Abstract Considerable variability across individuals has
been reported in both the behavioral and fMRI blood
oxygen level-dependent (BOLD) response to nicotine. We
aimed to investigate (1) whether there is a heterogeneous
effect of nicotine on behavioral and BOLD responses
across participants and (2) if heterogeneous BOLD
responses are associated with behavioral performance
measures. In this double-blind, placebo-controlled, cross-
over study, 41 healthy participants (19 smokers)—drawn
from a larger population-based sample—performed a visual
oddball task after acute challenge with 1 mg nasal nicotine.
fMRI data and reaction time were recorded during
performance of the task. Across the entire group of
subjects, we found increased activation in the anterior
cingulate cortex, middle frontal gyrus, superior temporal
gyrus, post-central gyrus, planum temporal and frontal pole
in the nicotine condition compared with the placebo
condition. However, follow-up analyses of this difference
in activation between the placebo and nicotine conditions
revealed that some participants showed an increase in
activation while others showed a decrease in BOLD
activation from the placebo to the nicotine condition. A
reduction of BOLD activation from placebo to nicotine was
associated with a decrease in reaction time and reaction
time variability and vice versa, suggesting that it is the
direction of BOLD response to nicotine which is related to
task performance. We conclude that the BOLD response to
nicotine is heterogeneous and that the direction of response
to nicotine should be taken into account in future
pharmaco-fMRI research on the central action of nicotine.
Keywords Nicotine . Functional magnetic resonance
imaging (fMRI) . Visual oddball . Reaction time
Introduction
Nicotine is known to enhance cognitive functions in
animals and humans (Levin et al. 2006). Given that
nicotinic agonists are being investigated as treatments for
cognitive deficits associated with a range of neuropsychi-
atric conditions including Alzheimer dementia, schizophre-
nia, and attention deficit disorder (Newhouse et al. 2004;
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Taly et al. 2009), a thorough understanding of the neural
mechanisms by which nicotine improves cognitive perfor-
mance is necessary. Considerable variability across studies
has been reported in both the behavioral and functional
magnetic resonance imaging (fMRI) blood oxygen level-
dependent (BOLD) response to nicotine. For example,
while numerous animal and human experiments illustrate
the cognitive enhancing properties of nicotine (Kumari et
al. 2003; Lawrence et al. 2002; Levin et al. 2002; Levin and
Chen 2004; Thiel et al. 2005), significant improvements in
performance are not always observed on all behavioral
measures (Ettinger et al. 2009; Giessing et al. 2006;
Jacobsen et al. 2004). Equivocal findings regarding the
effects of nicotine on task-related BOLD responses have
also been reported (Ettinger et al. 2009). Some studies find
a decrease in task-related BOLD activation in response to
nicotine (Giessing et al. 2006; Thiel et al. 2005; Thiel and
Fink 2008) others find an increased BOLD activation in
response to nicotine (Jacobsen et al. 2004; Kumari et al.
2003; Lawrence et al. 2002) while some further studies
report that nicotine enhances task-induced BOLD deactiva-
tions (Hahn et al. 2007, 2009). This heterogeneity in
responses could be due to many factors, such as type of
task/cognitive function under investigation, dose of nico-
tine, method of nicotine administration, and sample
characteristics. However, it could also be related to
individual responses to nicotine and the associated task
performance.
At present, the precise relationship between the changes
in BOLD activation in response to nicotine and perfor-
mance measures has not been sufficiently clarified. Some
studies suggest that a reduction in BOLD response under
nicotine compared with placebo represents more “efficient”
processing and is therefore representative of improved
performance (Giessing et al. 2006; Thiel et al. 2005). Other
studies, however, suggest that an increase in BOLD
activation in response to nicotine compared with placebo
is indicative of improved performance (Kumari et al. 2003;
Lawrence et al. 2002). In addition, not all studies find a
relationship between BOLD responses to nicotine and the
effects of nicotine on behavioral measures. For example, in
a study by Ettinger et al. (2009), both the behavioral and
BOLD responses to nicotine were found to be heteroge-
neous, but the nicotine effects on behavioral measures and
BOLD were found to be unrelated. Given the apparent
inter-subject heterogeneity of both the behavioral and
BOLD response to nicotine, investigation of the relation-
ships between these response modalities could be key to
understanding the effects of nicotine on cognition—and by
extension the nicotinic system's properties in the brain.
The study presented here focuses on responses to a
visual two-choice reaction time task with infrequent target
stimuli similar to that of an oddball task. The oddball task is
used in event-related potential (ERP) studies to elicit the P3
component of the ERP that represents target detection/event
categorization (Halgren et al. 1998; Picton 1992) or more
broadly, is considered to reflect selective attention and—to
some extent—working memory processes (Gur et al. 2007;
Javitt et al. 2008). The fMRI response to tasks that also
evoke the ERP P3 in electrophysiological experiments
involves a large distributed network including the supra-
marginal gyrus, frontal, insula, thalamus, cerebellum,
occipital–temporal, superior temporal, and cingulate
regions (Bledowski et al. 2004; Thiel et al. 2005; Gur et
al. 2007; Musso et al. 2006; Winterer et al. 2007; Strobel et
al. 2008). Given that a nicotine challenge has been shown
to influence behavioral and electrophysiological responses
to the oddball task (Froelinger et al. 2009; Polich and
Criado 2006) and that the task elicits a robust BOLD
response, it provides a suitable framework for investigating
the effects of nicotine on behavioral and fMRI measures of
attention and working memory. Thus, the aims of the
present study were twofold: (1) To investigate whether
there is a heterogeneous effect of nicotine on behavioral
and BOLD responses to target stimuli across participants
and (2) if heterogeneous BOLD responses are present to
investigate whether an improvement in performance is
related to the heterogeneous changes in the BOLD
response.
Methods
Participants
Forty-five healthy smoking and non-smoking participants
were recruited from a large population-based database in
Germany (Mobascher et al. 2010) with no history of
medical, neurological, or psychiatric illness (DSM-IV axis
1) or alcohol and drug abuse within past 6 months as
assessed by a full medical interview and examination,
routine laboratory tests, a drug screening test, an electro-
cardiogram, and a standardized psychiatric interview (First
et al. 1995). Smokers were only included in the study if
their Fagerström test for nicotine dependence (FTND) score
was ≥4 (Heatherton et al. 1991). Non-smokers were
included if they had smoked less than 20 cigarettes/lifetime.
All subjects were right-handed, as assessed by Edinburgh
Handedness Inventory (Oldfield 1971).
Data were discarded of two participants due to motion
artifacts during imaging measurements, of one participant
because of poor task performance (defined as fewer than
90% correct responses), one participant due to technical
difficulties and two participants due to being left handed
(handedness was not an exclusion criterion for the broader
clinical trial from which this sample was drawn). This
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resulted in data for 39 healthy participants [18 smokers, six
male; mean age 33.6 years (SD=10.9), and 21 non-
smokers, 11 male, mean age 32.6 years (SD=10.5)] being
included in the analysis (see Table 1).
Study procedure
The study (ClinicalTrial.gov Identifier: NCT00618280)
employed a double-blind, placebo-controlled, within-
subject, randomized, cross-over (counterbalanced) design
and was conducted in compliance with the declaration of
Helsinki in its latest version and according to ICH-GCP
(good clinical practice) guidelines following a strict
standard operating procedure with regular external moni-
toring. Written informed consent was obtained from all
participants. The study was approved by the ethics
committee of the Heinrich-Heine University, Düsseldorf
and the federal drug agency in Germany, i.e., the
Bundesinstitut für Arzneimittel and Medizinprodukte
(BfArM).
Participants (current smokers and non-smokers) were
investigated in the context of a multi-session pharmacolog-
ical fMRI study before and after overnight nicotine
withdrawal. The interim analyses presented here focus on
the experimental sessions from the first day, i.e., before
overnight nicotine withdrawal. Participants were admitted
to the clinical research unit of the Research Center Jülich
for the entire duration of the study. Before admission,
smokers were asked to smoke ad libitum with most
participants taking the possibility to have their last cigarette
right before admission. After admission, smokers remained
abstinent throughout the course of the study. Within 1 h
after arrival at the research center, participants completed
the Questionnaire on Smoking Urges (QSU; Tiffany and
Drobes 1991) which is a state-sensitive measure to assess
nicotine craving, levels of exhaled carbon monoxide (CO)
were measured using a Micro 4 Smokerlyzer® (Bedfont
Scientific Ltd.) and plasma was collected for cotinine
immunoassay measurements (DRI® Cotinine Assay, Micro-
genics, Passau, Germany). Participants also completed the
Wechsler IQ Scale (Wechsler 1987) as a measure of
intelligence.
All participants completed two 1-h experimental sessions
in the MRI scanner 4 h apart with the first session being
approximately 2 h after admission. The experimental
sessions were conducted after acute challenge with 1 mg
nasal nicotine spray® (0.5 mg each nostril) or placebo
(pepper) spray. One milligram nicotine delivered by nasal
spray is largely bioequivalent with nicotine consumption by
smoking one cigarette (Benowitz and Jacob 1984). A
between-session interval of 4 h was chosen for the
following reasons. Half-life time of nicotine is 2 h
(Benowitz et al. 1982), i.e., 75% of nicotine (administered
by nasal spray) is metabolized after 4 h (including the
duration of the first MR scan of 1 h). At the same time, this
relatively short time interval is considered a reasonable
compromise to avoid that smokers develop serious with-
drawal symptoms which may themselves have an effect on
brain function (Polich and Ochoa 2004). In order to account
for the unavoidable remaining effects of lingering nicotine
and beginning withdrawal, the order of the placebo and
nicotine challenge was randomized and counterbalanced
across participants.
Behavioral task
Participants performed a visual choice reaction oddball task
consisting of 64 infrequent “target” stimuli and 256 frequent
stimuli (one additional cognitive task was also performed but
is not reported here). Stimuli were black and white checker-
boards, the infrequent target stimuli were identified as a
reversal of the pattern of the frequent stimuli. A black screen
was presented between stimuli. Stimuli were presented using
Presentation version 11.3 (Neurobehavioural systems®,
Albany, CA, USA) via a screen situated behind the scanner.
Participants were able to view the screen via a mirror mounted
on the head coil. Participants' responses were recorded using
Lumitouch key pads® (Photon Control Inc, Burnaby, BC,
Canada). For infrequent stimuli, participants responded with
their right index finger, and for frequent stimuli, they
responded with their left index finger; they were asked to
respond quickly and accurately to each stimulus and reaction
time was recorded for each response. Stimuli were presented
Table 1 Demographic and clinical information
Variable Smokers Non-smokers
Subject number 18 21
Age, mean (SD),years 33.6 (10.9) 32.6 (10.5)
Male (N) 6 11
Female (N) 13 10
IQa 101.8 (10.2) 102.6 (9.8)
FTND score, mean (SD) 5.1 (2.0) –
CO, mean (SD), ppm 17.3 (11.18) –
QSU, mean (SD) 104.47 (30.23) –
Plasma cotinine, mean
(SD) (ng/ml)b
127.9 (116.2) –
FTND Fagerström test for nicotine dependence score was≥4 (Heatherton
et al. 1991)
QSU Questionnaire on Smoking Urges (Tiffany and Drobes 1991) to
assess craving
CO levels of carbon monoxide in expired air
IQ Wechsler Memory Scale (Wechsler, 1987).
a Smokers N=18, non-smokers, N=18, data unavailable for three subjects
b Smokers N=16, plasma cotinine data unavailable for two subjects
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with duration of 1,000 ms and a pseudorandomized
interstimulus interval (ISI) of 4,000 (±500)ms. Only
responses to target stimuli were of interest (see fMRI analysis
section below); the target-to-target ISI was 22 s (SD 23 s).
fMRI data acquisition
Functional MR-images were acquired using a 3T scanner
(TIM-Trio®, Siemens, Erlangen, Germany). Using echo
planar imaging (EPI), 630 volumes were obtained applying
the following EPI parameters of 33 slices; slice thickness,
3 mm; interslice gap, 0.3 mm; field of view (FOV), 200×
200 mm; 64×64 matrix; repetition time, 2,000 ms; echo
time, 30 ms; and flip angle, 90°. To facilitate localization
and co-registration of functional data, structural scans were
acquired using T1-weighted MRI sequences [magnetization
prepared rapid gradient echo: TR/TE=2250/3.03 ms, flip
angle=9°, 176 sagittal slices, FOV 200×200mm, 64×64
matrix, voxel size 1×1×1 mm.
Simultaneous EEG recordings were also conducted
during fMRI scanning. These data will not be reported in
the current study.
fMRI analysis
Single-subject imaging analyses were conducted blind for
drug condition (placebo vs. nicotine). fMRI analysis was
performed with FSL (FMRIB's Software Library, www.
fmrib.ox.ac.uk/fsl); employing different modules of the
FSL-software package, motion correction was performed
using MCFLIRT (FMRIBs Linear Registration Tool,
Jenkinson et al. 2002), non-brain removal using BET
(Smith 2002), spatial smoothing using a Gaussian kernel
of FWHM=8 mm, mean based intensity normalization of
all volumes by the same factor, and high-pass temporal
filtering (sigma=125 seconds). General linear model
(GLM) time-series statistical analysis of individual data
sets was carried out using FILM (FMRIB's Improved
Table 2 Brain regions and local maxima of responses to target stimuli
Region (Harvard-Oxford,
maximum probability)
MNI coordinates of local
maxima (X, Y, Z)a
Max. Z
score
Region (Harvard-Oxford,
maximum probability)
MNI coordinates of local
maxima (X, Y, Z)
Max. Z
score
Left hemisphere Right hemisphere
Post-central gyrus −44, −24, 50 −56, −26, 48 6.84 6.43
Pre-central gyrus −40, −16, 56 −36, −18, 56 6.44 6.38 Pre-central gyrus 46, 8, 26 5.16
Parietal opercular cortex −50, −26, 20 6.65
Supramarginal gyrus −54, −28, 42 6.35 Supramarginal gyrus 44, −36, 42 4.72
Cerebelluma (left) −32, −54, −26 3.78 Cerebelluma (right) 16, −52, −26 5.87
Inferior lat occ cortex,
superior lat occ cortex
−44, −78, −12 4.86 Inferior lat occ cortex,
superior lat occ cortex
34, −90, −4 5.82
−32, −88, 14 3.96 20, −66, 50 4.88
Superior parietal lobule 28, −54, 52 5.05
Insular cortex −44, 2, −2 5.52 Insular cortex 34, 24, −2 5.25
−40, 6, −2 5.07
Supplementary motor area −6, 2, 46 5.41 Supplementary motor area 8, 6, 50 3.63
Cingulate gyrus (anterior) −6, 2, 44 5.26 Cingulate gyrus (anterior) 6, 20, 32 4.81
Cingulate gyrus (posterior) −2, −30, 26 3.72
Occipital pole −30, −98, 0 5.22 Occipital pole 34, −90, 2 5.57
−34, −92, −6 5.02 26, −100, 4 5.36
Temporal occipital fusiform
cortex
30, −52, −20 5.37
Frontal orbital cortex −30, 26, −2 3.61 Frontal orbital cortex 34, 26, −2 5.2
Inferior frontal gyrus 48, 10, 28 5.12
Thalamus −12, −20, 4 5.09
Brain-stem −4, −28, −12 4.89
Occipital fusiform gyrus −40, −66, −12 4.89 Occipital fusiform gyrus 42, −64, −14 3.75
Superior frontal gyrus −22, −8, s72 4.86 Superior frontal gyrus 12, 2, 72 3.55
Frontal pole 44, 44, 18 3.87
Whole-brain voxelwise analysis (N=39, smokers and non-smokers, cluster-corrected at Z=2.3, p=0.05)
aMontreal Neurological Institute (MNI) label
lat occ lateral occipital
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Linear Model) with local autocorrelation correction
(Woolrich et al. 2001). Registration of functional images
to high-resolution structural images was done with FLIRT
(FMRIB's Linear Image Registration Tool, Forman et al.
1995; Jenkinson et al. 2002). Responses to target stimuli
were modeled with an explanatory variable constructed
using onset times of target stimuli only, convolved with a
gamma hemodynamic response function. An explanatory
variable containing the onsets of the frequent (non-target)
stimuli was also included as a variable of no interest. The
resulting activation maps represent BOLD responses to
target stimuli compared with baseline (target stimuli>
baseline). Group-level mixed-effect analyses were con-
ducted using FLAME (FMRIB's Local Analysis of Mixed
Effects; Behrens et al. 2003) with spatial normalization to
MNI (Montreal Neurological Institute) space and applying
a cluster significance threshold of Z>2.3 (Forman et al.
1995; Friston et al. 1994; Worsley et al. 1992). The
following group-level analyses were conducted: Group
means were created for the placebo and nicotine sessions
separately to determine the overall activation pattern.
Differences between groups (smokers and never-smokers)
were investigated using an independent sample t test;
differences between the placebo and nicotine sessions were
investigated with a paired sample t test. To investigate the
relationship between the nicotine effect on BOLD response
and the nicotine effect on reaction time, additional analyses
were conducted with change in reaction time and change in
reaction time standard deviation included as covariates. A
second-level fixed-effects analysis (placebo vs nicotine)
was performed for each subject to give a statistic
representing the difference between the placebo and
nicotine conditions. These data were then taken through to
group-level mixed-effects analyses where the reaction
difference values were included as covariates. Functional
data were imported to MRIcron (Rorden et al. 2007) for
visual display purposes.
Region-of-interest analysis
The nicotine>placebo group-level contrast (for target
stimuli>baseline) revealed a pattern of increased activation
in the nicotine condition compared with placebo (see
Results section). To investigate whether all participants
showed an increase in activation from placebo to nicotine a
region-of-interest (ROI) mask was created based on overall
activation in this contrast. This mask was 3,406 voxels in
size and encompassed clusters in the following regions:
anterior cingulate cortex (ACC), middle frontal gyrus,
frontal orbital cortex, superior frontal gyrus, and frontal
pole. (see Results section for details). Mean percent signal
change (parameter estimate) in the region-of-interest was
exported for each participant for each session. A difference
value for nicotine-placebo was then calculated to assess
whether each participant showed a decrease or an increase
in BOLD activation from placebo to nicotine. This
difference in activation between the placebo and nicotine
conditions is not to be confused with deactivation which is
considered to be a reduction in BOLD signal compared
with baseline in response to a task and has been associated
with the nicotine response (Hahn et al. 2007, 2009). What
we are looking at here is the difference in the BOLD
response between the placebo and nicotine condition,
whether a particular subject has more or less activation
(target>baseline) in the nicotine condition compared with
the placebo condition.
Statistical analysis
A 2×2 (drug×smoking status) analysis of variance
(ANOVA) was conducted to test for nicotine and smoking
status effects on the following dependent variables: mean
BOLD percent signal change, mean reaction time, and
reaction time standard deviation.
Relationships between the following variables were tested
with Pearson correlation coefficient r: difference in mean
percent signal change between the placebo and nicotine
conditions and the difference in reaction time (RT) measures
between placebo and nicotine conditions; and between
smoking-related variables (QSU, FTND, CO, cotinine) and
mean percent signal change in the ROI and RT variables.
Results
Behavioral data
All participants performed the task with an average of
98.9% (SD 2.43%) and 99.2% (SD 2.2%) correct responses
Table 3 Regions activated in the nicotine vs placebo contrast
Region (Harvard-Oxford,
maximum probability)
MNI coordinates
of local maxima
(X, Y, Z)
Maximum
Z value
Middle frontal gyrus (R) 30 16 32 3.83
Middle frontal gyrus (L) −54 16 38 2.94
ACC (R) 2 24 34 3.09
Frontal orbital cortex (R) 32 20 −24 3.86
Frontal orbital cortex (L) −42 30 −4 2.34
Pre-central gyrus (R) 50 −6 34 2.78
Pre-central gyrus (L) −60 8 34 3.8
Lateral occipital cortex (L) −24 −64 50 3.64
Frontal pole (R) 30 50 −16 2.82
Whole-brain voxelwise analysis (N=39, smokers and non-smokers,
cluster-corrected at Z=2.3, p=0.05)
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to target stimuli for the placebo and nicotine session,
respectively. No false responses were recorded, but an
average of 1.0% (SD 2.4 %) and 0.8% (SD 2.2%) target
stimuli were missed for the placebo and nicotine sessions,
respectively. Mean RT to target stimuli for the placebo
session was 630.3 ms (SD=75.5) and for the nicotine session
was 626.3 ms (SD 79.9). A 2×2 (drug×smoking status)
ANOVA revealed no differences in mean reaction time or
reaction time standard deviation between the placebo and
nicotine conditions (F(1,37)=0.22, P=0.64, F(1,37)=0.38,
P=0.54, respectively) or between smokers and non-
smokers [F(1,37)=0.93, P=0.34, F(1,37)=0.1.21, P=0.28,
respectively). Furthermore, the drug×smoking status inter-
actions failed to reach significance [F(1,37)=0.001,
P=0.98, F(1,37)=0.18, P=0.67, respectively).
fMRI data—overall nicotine effects
The BOLD analysis (N=39) revealed activation in
response to infrequent target stimuli in the post-central
gyrus, pre-central gyrus, cerebellum, supramarginal gyrus,
insula, frontal operculum, inferior frontal gyrus, middle
frontal gyrus, anterior cingulate cortex, and lateral occip-
ital cortex (Fig. 1.; see Table 2 for MNI coordinates and Z
values). Group-level analyses revealed no significant
differences in whole-brain voxelwise BOLD activation
between smokers and non-smokers for both the placebo
and nicotine conditions. Within the group of smokers,
smoking behavior-related variables, FTND, QSU, expired
CO, and plasma cotinine, were not related to any of the
behavioral or fMRI measures (Supplemental Table 1).
Since no differences were found between the smokers and
non-smokers on any measure and no relationships were
found between the smoking-related variables and BOLD
or reaction time measures, the smokers and non-smokers
were considered as one group in all further analyses.
Across all participants, there was a significant difference
in BOLD activation between the placebo and nicotine
condition in the anterior cingulate cortex, middle frontal
gyrus, superior frontal gyrus, pre-central gyrus, planum
temporal, lateral occipital cortex, supramarginal gyrus, and
frontal pole (see Fig. 2; Table 3) with there being more
activation in the nicotine condition than the placebo
condition (nicotine>placebo contrast).
ROI analyses
A ROI mask was created from the overall (nicotine>
placebo) activation map. The mean percent signal change in
this ROI was then extracted for each participant for each
session. The difference in mean percent signal changes
between the placebo and nicotine sessions were calculated
for each participant. Some participants showed an increase
in activation from placebo to nicotine, and others showed a
decrease. Again, this difference in activation between the
placebo and nicotine conditions is not to be confused with
deactivation; we are looking at whether a subject shows
more or less activation in the nicotine condition compared
with the placebo condition. In addition to individual
subjects showing differential BOLD responses to nicotine
(i.e., some show an increase while others show a decrease),
significant relationships between this difference value and
performance measures were observed. As depicted in
Fig. 3, shortening of reaction time from placebo to nicotine
condition was accompanied by a decrease in BOLD
activation [r(37)=0.43, P=0.007]. Likewise, a decrease in
reaction time variability from placebo to nicotine condition
was related to a reduction of BOLD activation [r(37)=
0.51, P=0.001]. For clarification of the absence of differ-
ences between smokers and non-smokers, a 2×2 (drug×
smoking status) ANOVA was performed on mean percent
signal change in the ROI. There was a significant main
effects for drug [F(1,37)=14.69, P<0.001], which was to
be expected due to the ROI being based on the nicotine>
Fig. 1 BOLD activation for the
group-level analysis (second-
level mixed-effects FLAME;
N=39, cluster-corrected
threshold Z=2.3, p=0.05)
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placebo contrast. However, no difference was found
between smokers and non-smokers [F(1,37)=1.09, P=30],
the drug by smoking status also failed to reach significance
[F(1,37)=0.11, P=0.74).
fMRI data—relationship to behavioral response
To further investigate the relationship between nicotine
effects on the BOLD response and nicotine effects on
behavioral measures, the difference in reaction time and
reaction time standard deviation were included as cova-
riates in the GLM (see Methods for details). The change in
mean reaction time was positively related to the activation
in the nicotine>placebo contrast (Fig. 4). In other words, an
increase in BOLD activation from placebo to nicotine was
related to an increase in reaction time from placebo to
nicotine and vice versa. The regions in which BOLD
activation correlated with mean reaction time were as
follows: middle frontal gyrus, planum temporale, frontal
orbital cortex, superior parietal lobule, lateral occipital
cortex, post-central gyrus, pre-central gyrus, and anterior
cingulate cortex. A positive relationship to BOLD activa-
tion was also found for reaction time standard deviation in
the following regions: middle frontal gyrus, frontal orbital
cortex, inferior temporal gyrus, lateral occipital cortex,
planum temporale, pre-central gyrus, and post-central
gyrus. Both mean reaction time and reaction time standard
deviation were related to the nicotine effect on the BOLD
response in similar regions, and these regions largely
overlap with the overall nicotine effect on BOLD response,
suggesting that the behavioral response and BOLD
response are indeed closely linked (Table 4).
Discussion
We investigated the effects of acute nasal spray nicotine
challenge on BOLD fMRI and behavioral responses to a
visual oddball task. Group-level analysis revealed BOLD
activation in response to infrequent target stimuli in brain
regions consistent with previous research (Halgren et al.
1995a, b; Gur et al. 2007; Strobel et al. 2008; Winterer et
al. 2007). Smokers and non-smokers did not differ on any
behavioral or BOLD measures. Applying standard group
contrast analyses between the nicotine and placebo con-
ditions, increased activation was found in the post-central
gyrus, pre-central gyrus, cerebellum, supramarginal gyrus,
insula, frontal operculum, inferior frontal gyrus, middle
frontal gyrus, anterior cingulate cortex, and lateral occipital
cortex while no significant behavioral group differences
(mean reaction time and reaction time standard deviation)
were found. However, when individual response patterns
were examined more closely, it was found that some
subjects showed an increase in activation in the nicotine
Fig. 2 BOLD activation for the
placebo versus nicotine contrast
(paired t test) (second-level
mixed-effects FLAME. N=39,
cluster-corrected threshold
Z=2.3, p=0.05)
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condition compared with the placebo condition while others
showed a decrease. This difference in BOLD activation
between the two conditions was also related to nicotine
effects on behavioral performance.
Contrasting the nicotine with the placebo condition on
the group level, we found increased activation in the post-
central gyrus, pre-central gyrus, cerebellum, supramarginal
gyrus, insula, frontal operculum, inferior frontal gyrus,
middle frontal gyrus, anterior cingulate cortex, and lateral
occipital cortex in the nicotine condition compared with the
placebo condition (nicotine>placebo). By and large, this
result is consistent with several earlier reports of an
increased BOLD response for varying task conditions
(Jacobsen et al. 2004; Kumari et al. 2003; Lawrence et al.
2002). Furthermore, the direction and magnitude of the
nicotine effects on the BOLD response in these regions was
related to the nicotine effects on mean reaction time and
reaction time standard deviation. Specifically, faster reac-
tion times and reduced reaction time variability were
associated with reduced BOLD activation under nicotine
compared with placebo.
The diversity of regions that are apparently influenced
by nicotine across studies and paradigms suggests that
nicotine acts on several sub-processes of attention and
working memory whereby different task conditions
emphasize different cortical regions. The rather uniform
nicotine effect across regions is in accordance with
neuroimaging and neuroanatomical studies showing a
rather homogeneous density of nicotinic receptors
throughout human cortex (Hellström-Lindahl et al. 1999;
Gallezot et al. 2005) although one post-mortem study
reported a relative increase of nicotinic binding sites in
parietal cortex (Scheperjans et al. 2005). The finding from
our study also fits with what is known about nicotinic/
cholinergic neurotransmission and cognition. For instance,
binding of nicotine to nicotinic receptors enhances
visuospatial and sustained attention (Hahn et al. 2009;
Newhouse et al. 2004). Furthermore, dopaminergic neu-
rotransmission plays a central role in working memory,
and nicotine-stimulated dopamine release has been shown
to impact on working memory task performance (Jacobsen
et al. 2006).
While our overall group-level response to nicotine is
consistent with previous research, the degree and direction
of the difference in BOLD activation between the placebo
and nicotine condition showed substantial inter-individual
variation. This variation was also related to reaction time
performance. In response to nicotine compared with
placebo, some participants showed faster reaction times
together with reduced reaction time variability, and this
was associated with reduced BOLD activation. The
opposite observation was made for those participants with
a nicotine response-related slow-down of reaction time
and increase of reaction time variability. Thus, despite an
overall increase of BOLD activation in response to
nicotine, inter-individual variability in responses was
observed. Overall, the observation of heterogeneous
nicotine effects on BOLD response with regard to the
direction of change is in line with other recent studies
(Ettinger et al. 2009; Giessing et al. 2007). However, we
Fig. 3 Scatter plots showing the relationship between fMRI BOLD
and behavioral responses to nicotine. a The difference in mean
reaction time (RT) and the difference in mean percent signal (BOLD
in the placebo vs nicotine ROI between the placebo and nicotine
conditions. Difference values were calculated by subtracting the value
for the placebo condition from the value for the nicotine condition.
For mean percent signal change, a negative difference value represents
a decrease in activation from placebo to nicotine. A positive value
represents an increase from placebo to nicotine. For mean RT, a
negative value indicates a reduction in reaction time from placebo to
nicotine and a positive value represents an increase in reaction time
from placebo to nicotine. A decrease in reaction time from placebo to
nicotine is related to a decrease in BOLD activation from placebo to
nicotine (b). The difference in reaction time standard deviation
(RT_SD) and the difference in mean percent signal change in the
placebo vs nicotine ROI between the placebo and nicotine conditions.
For RT_SD, a negative value indicates a reduction in reaction time
variability from placebo to nicotine and a positive value represents an
increase in reaction time variability from placebo to nicotine. A
decrease in reaction time variability from placebo to nicotine is related
to a decrease in BOLD activation from placebo to nicotine
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show here for the first time that this heterogeneous
nicotine response is functionally significant as reflected
by its relationship to performance.
The reaction time-related nicotine effect in the ACC,
superior parietal, inferior temporal, and lateral occipital
regions is particularly interesting, since activation in these
regions is consistent with previous research and expected
modulation in relation to our task. The ACC is associated
with executive and evaluative functions, and its involve-
ment in our task is consistent with other fMRI studies of
target detection and decision making (Gur et al. 2007;
Philiastides and Sajda 2007; Sridharan et al. 2008).
Specifically, we found activation in the left and right dorsal
ACC. The dorsal ACC is connected to the prefrontal cortex
and parietal cortex as well as the motor system and the
frontal eye fields, i.e., it plays an important role in
Fig. 4 BOLD activation for the placebo versus nicotine contrast with
reaction time data included as a covariate (second-level mixed-effects
FLAME, N=39, cluster-corrected threshold Z=2.3, p=0.05). The left
panel shows activation associated with the nicotine effects on mean
reaction time. The right panel shows activation associated with the
nicotine effects on reaction time standard deviation
Table 4 Brain regions and local maxima where BOLD activation is related to behavioral performance
Region (Harvard-Oxford,
maximum probability)
MNI *coordinates
of local maxima (X, Y, Z)
Max. Z
score
Region (Harvard-Oxford,
maximum probability)
MNI coordinates
of local maxima (X, Y, Z)
Max. Z
value
Mean reaction time Reaction Time SD
Middle frontal gyrus (R) 30 16 32 3.92 Middle frontal gyrus (R) 30 16 32 3.86
Planum temporale (L) 40 −38 14 3.90 Frontal orbital cortex (L) 32 20 −24 3.87
Frontal orbital cortex (R) 32 20 −24 3.85 Inferior temporal gyrus −44 −52 −16 3.83
Superior parietal lobule (R) 44 −38 58 3.80 Lateral occipital cortex (L) −24 −62 64 3.83
Lateral occipital cortex (L) −24 −62 50 3.76 Planum temporale (R) 40 −38 14 3.79
Post-central gyrus (R) −50 −36 60 3.71 Pre-central gyrus (L) −62 10 32 3.73
Pre-central gyrus (R) −60 10 32 3.70 Post-central gyrus (R) −48 −40 58 3.68
Anterior cingulate cortex (L) −6 −6 38 3.10 Anterior cingulate cortex (L) −6 −6 40 2.91
Whole-brain voxelwise analysis (N=39, smokers and non-smokers, cluster-corrected at Z=2.3, p=0.05)
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processing top-down and bottom-up stimuli and assigning
appropriate control to other areas in the brain (Paus 2001).
The ACC is also thought to be part of the so-called Salience
Network (Sridharan et al. 2008) that is involved in
processing the degree of subjective salience and typically
shows an increase in activation in response to a cognitive
task. Since ACC activation also depends on cholinergic
neurotransmission (Sarter et al. 2006), it is therefore not
unexpected that the ACC is particularly strongly engaged in
the target detection task used in the present nicotine
challenge study. If an increase in ACC activation represents
increased processing or effort, then a reduction in task-
related ACC activation in response to nicotine compared
with placebo could be interpreted as more “efficient”
processing under nicotine. This might provide a
phenomenology-based explanation of the relationship
found between reduced ACC activation and improved
reaction time performance between the placebo and
nicotine conditions.
We also found that activation in the parietal cortex
(specifically, the superior parietal lobule and post-central
gyrus) differed between the placebo and nicotine condi-
tions, consistent with other studies (Thiel et al. 2005; Thiel
and Fink. 2008; Giessing et al. 2007; Vossel et al. 2008).
The studies by Thiel and colleagues showed a decrease in
parietal BOLD activation under nicotine compared with
placebo, and this was accompanied by a tendency for a
reduction in reaction time under nicotine compared with
placebo. These findings thus support the idea that a
reduction in BOLD activation in response to nicotine
compared with placebo is related to improvements in
performance. Similar performance efficiency-related reduc-
tions in BOLD signal have also been observed for other
compounds. For example, Dodds et al. (2008) observed that
methylphenidate reduced BOLD signal in the ventral
putamen during a switching task after negative feedback
and speculated that, in absence of any behavioral effect of
the drug, the reduction in BOLD signal may reflect an
increase in the efficiency of executive control (Dodds et al.
2008). In addition, the COMT (catecholamine-O-methyl-
transferase) inhibitor tolcopone was shown to reduce
BOLD activation in the dorsolateral prefrontal cortex in
tasks involving memory and executive function; this was
associated with an improvement in performance (Apud et
al. 2007). This matches our own findings in that a reduction
in BOLD activation from placebo to nicotine was related to
a reduction in reaction time variability from placebo to
nicotine. Given that, for some participants activation
decreased from placebo to nicotine and for others activation
increased from placebo to nicotine, this activation in the
parietal cortex could reflect a more efficient processing in
some participants. So, those that improve their performance
also show reduced parietal activation under nicotine. The
same principle can be applied to the activation observed in
the inferior temporal gyrus and lateral occipital cortex. The
inferior temporal gyrus is part of the higher level of the
ventral stream of visual processing and is involved in object
recognition. The lateral occipital cortex is not only
indicative of processing visual stimuli but has also been
implicated in attention allocation (Weissman et al. 2006;
Goldman et al. 2009). These regions also showed a reaction
time-related decrease in activation in response to nicotine,
suggesting that they are also involved in this improved
efficiency due to enhanced cholinergic signaling under
nicotine. It is interesting to note that this more efficient
processing is also reflected in less variable performance as
well as an improvement in mean reaction time. Vossel et al.
(2008) also found that nicotine reduced the variability of
reaction times in a cue validity task, but only when validity
was high. The reduction in activation in the parietal regions
could therefore be the neural mechanism underlying the
reduction in response variability observed in our data.
Finally, the question arises whether the group-level
difference in response to nicotine between our investigation
and, for instance, the study of Thiel et al. (2005) or Vossel
et al. (2008) is simply dependent on different task
conditions. We found an overall, group-level increase in
BOLD activation in response to nicotine, which, given the
relationship between BOLD and reaction time revealed in
our data, suggests that our group performed less well under
nicotine. However, our task was a simple target detection
task, and the tasks employed in other studies have different
cognitive demands. An alternative explanation, also to be
taken into account, is that the heterogeneous nicotine
response reflects—at least, in part—sample heterogeneity.
Thus, as opposed to previous imaging studies on nicotine
effects, our study was population-based rather than recruit-
ing, for instance, mainly students for the experiment. In
future investigations of nicotine effects, these questions
should be addressed more systematically.
In summary, we confirm the observation of considerable
variability in the response direction of BOLD signaling to
nicotine across participants. For the first time, it is shown
that this response direction is behaviorally meaningful. We
suggest that this is likely to contribute to the equivocal
findings observed across studies reported in literature.
There is a wealth of research suggesting that nicotine does
have an effect on cognition, in terms of performance on
attention and working memory tasks, but many factors may
influence whether nicotine has a beneficial, detrimental, or
no effect on the individual. For example, factors to
investigate in the future include genetic factors, receptor
availability, and withdrawal effects. Furthermore, aspects of
experimental design, such as task, mode of nicotine
administration, and sample characteristics can also influ-
ence the measured responses to nicotine. Consideration of
342 Psychopharmacology (2011) 215:333–344
all factors is beyond the scope of this paper; however, it
would be interesting to find out whether the response
direction to nicotine has any implications for psychiatric
disorders or patients who are thought to potentially benefit
from nicotine agonists.
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